argenx’s Post

Can't we increase not find a solid state electrolyte that would act as a reducer for depolarization of cell membrane like the new lithium batteries? I don't really know anything about science, but I like to imagine possibilities. 😀 #houseoflovingawareness #coloradomentalwellnessinitiative #willojontv #neurology #science #mentalhealth #mentalhealthmatters #mentalwellness #americanspiritsthemovie

I am proud of the Phase 3 data #MyCompany, Johnson & Johnson Innovative Medicine presented at the 2024 European Academy of Neurology Meeting. For patients with generalized myasthenia gravis (gMG), a chronic, rare autoantibody-driven disease, more effective treatment options are crucial for improving quality of life. My colleagues and I are driven to address the remaining unmet needs in this space, and we are grateful to have collaborated with other industry experts who share this passion for purposeful scientific exploration at #EAN2024.    #JNJNeuroscience #JNJImmunology 

Intense basics of neurology Session 12: 22/06/2024 Topics: 1. Motor neuron 2. Motor neuron diseases 3. Spinal nerve formation 4. Dermatome and Myotome Timing: 8:20pm-9:40pm

Intense basics of neurology Session 11: 21/06/2024 Topics: 1. Introduction to spinal cord 2. Spinal cord tracts Timing: 7:30pm-8:20pm 3. Spinal cord Injuries Timing: 8:40pm-9:30pm

Interested in the highlights of the 2024 #PNS Annual Meeting? Check these #neuropathy session/symposium summaries I wrote for Focus on Neurology: https://lnkd.in/eV_QEamr I tried to cover different disease areas, drug life cycles, and presenters across the world. #CIDP #GBS #MMN #DPN #peripheralNeuropathy

February 29 is #RareDiseaseDay. Learn more about rare diseases in neurology through CNSA's Clinical Proceedings series ▶️ https://bit.ly/3a2xoEh

Next webinar 11.01.2024, Dr. Maxwell Damian: Respiratory insufficiency in Neuromuscular Diseases #EURONMD ERN-RND, European Reference Network for Rare Neurological Diseases European Academy of Neurology #EANeurology #webinars #neuromuscular #RareMuscleDiseases

Results from our Phase 2 Vivacity-MG study evaluating nipocalimab in adults with moderate-to-severe generalized myasthenia gravis were published in Neurology by the American Academy of Neurology. These results reinforce our path to progress in offering safer, more effective and tolerable treatment options to people living with this rare autoantibody disease of the nervous system.   I want to extend my gratitude to our dedicated research team and to our clinical trial participants, without whom we could not advance the science towards better therapeutics. Access the article here: https://bit.ly/3NCoRZp #MyCompany #MyastheniaGravis

If you are interested in better understanding the review process of each patient case at n-Lorem, please listen to this fascinating conversation between Jeff Carroll and Stanley Crooke, two inspiring people I have the chance to work with every day! #nanorare #nloremfoundation #careforrare

📣 In a new consensus statement published in Annals of Neurology, Scalfari and colleagues (2024) present evidence that current clinical guidelines may not sufficiently focus on the smouldering components of #multiplesclerosis, and that better understanding of smouldering-associated worsening (SAW) may help better track disease progression 🔥 🧠 They propose considering MS in terms of both its inflammatory and smouldering components. At icometrix, we share the authors' vision that the smouldering component of MS may provide much insight into a given patient's disease state, and should be assessed alongside the inflammatory component. Hence, our clinical #icobrain ms report is designed to emphasize the most clinically actionable metrics assessing disease progression in terms of both changes in inflammation and changes in brain volume. Further, our research-use icobrain ms+ report contains additional metrics that may relate to SAW, such as paramagnetic rim lesions, cervical spinal cord surface-area, and volumetrics of additional neural substructures. In this way, using icobrain ms allows clinicians to assess their patients using accurate, validated metrics which are in line with cutting edge clinical recommendations Congratulations on a milestone publication for the MS field Antonio Scalfari, Tony Traboulsee, Jiwon Oh, Laura Airas, Jose Manuel Garcia Dominguez, Cristina Granziera, Benjamin Greenberg, Kerstin Hellwig, Zsolt Illes, Jan Lycke, Veronica Popescu, Francesca Bagnato, Gavin Giovannoni For a link to the paper, see the comment below!